Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)

Journal of Inflammation Research

Volumn 3, Issue 1, 2010, Pages 1-8

  Gillespie, Justin ^a   Mathews, Rebeccah ^a   McDermott, Michael F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Autoinflammatory; Cryopyrin associated periodic syndromes; IL 1 TRAP; Inflammasome; Interleukin 1; Rilonacept

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1BETA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; ATHEROSCLEROSIS; BASAL CELL CARCINOMA; BONE DISEASE; CINCA SYNDROME; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; EYE INFLAMMATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEVER; GOUT; HUMAN; INCIDENCE; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DERMATITIS; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INJECTION SITE VESICLE; INJECTION SITE WARMTH; ISCHIALGIA; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; LOADING DRUG DOSE; LUNG FIBROSIS; MACROPHAGE ACTIVATION SYNDROME; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MOUTH ULCER; MUCKLE WELLS SYNDROME; NEUTROPENIA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; SKIN INFLAMMATION; STEADY STATE; SYMPTOMATOLOGY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 77953466981     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: None     Document Type: Review

References (46)

1. Neven B, et al. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol. 2008;4(9):481-489.
2. Hoffman HM. Hereditary immunologic disorders caused by pyrin and cryopyrin. Curr Allergy Asthma Rep. 2007;7(5):323-330.
3. Prieur AM, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl. 1987;66:57-68.
4. Hoffman HM, et al. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001;108(4):615-620.
5. Hoffman HM, et al. Mutation of a new gene encoding a putative pyrinlike protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301-305.
6. Hoffman HM, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364(9447):1779-1785.
7. Thornton BD, et al. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis. 2007;49(3):477-481.
8. Hawkins PN, et al. Interleukin-1-receptor antagonist in the MuckleWells syndrome. N Engl J Med. 2003;348(25):2583-2584.
9. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
10. Kogan-Sakin I, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009;30(4):698-705.
11. Ma FY, et al. Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest. 2009;89(4):470-484.
12. Tsuzaki M, et al. IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J Orthop Res. 2003;21(2):256-264.
13. Aksentijevich I, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340-3348.
14. Church LD, et al. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42.
15. Arostegui JI, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum. 2004;50(12): 4045-4050.
16. Aganna E, et al. Association of mutations in the NALP3/CIAS1/ PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 2002;46(9):2445-2452.
17. Martinon F, et al. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.
18. Muruve DA, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008; 452(7183):103-107.
19. Petrilli V, et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19(6):615-622.
20. Arend WP, et al. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20-38.
21. Ross JB, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg. 2008;12(1):8-16.
22. Goldbach-Mansky R, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432-2442.
23. Lachmann HJ, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416-2425.
24. Savic S, McDermott MF. Inflammation: canakinumab for the cryopyrinassociated periodic syndromes. Nat Rev Rheumatol. 2009;5(10):529-530.
25. Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin. 2008;24(6):1577-1582.
26. Economides AN, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9(1):47-52.
27. Hoffman HM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther. 2009;9(4):519-531.
28. Arcalyst (rilonacept) [prescribing information]. Tarrytown, NY: Regeneron, 2008.
29. Hoffman HM, et al. Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443-2452.
30. Roldan R, et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008;75(4):504-505.
31. Sacre K, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol. 2008;35(2): 357-358.
32. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial background and rationale. Diabetes Metab Res Rev. 2009;25(4):321-324.
33. Apostolakis S, et al. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem. 2008;6(2):150-158.
34. Terkeltaub R, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613-1617.
35. Lequerre T, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302-308.
36. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2009.
37. Rilonacept [IL-1 Trap, Arcalyst; Regeneron Pharmaceuticals] has reduced the incidence of gout flares in a phase II study. Inpharma. 2008;1(1655);9-9(1).
38. Haines KA. Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis. 2007;65(3):205-211.
39. Yokota S, et al. Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):818-825.
40. Pascual V, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479-1486.
41. Lovell DJ, et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11, 2007; Boston, Massachusetts. Abstract 1282.
42. Lovell DJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Program and abstracts of the American College of Rheumatology (ACR) Annual Meeting. October 17-21, 2009; Philadelphia. Presentation 2053.
43. Feldmann M, et al. Anti-TNF therapy: where have we got to in 2005? J Autoimmun. 2005;25 Suppl:26-28.
44. Eleishi HH, et al. Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh hospital in Jeddah, Saudi Arabia. Int J Rheum Dis. 2009;12:14-19.
45. Kapur S, Bonk ME. Rilonacept (Arcalyst), an interleukin-1 Trap for the treatment of cryopyrin-associated periodic syndromes. P T. 2009; 34(3):138-141.
46. Registered clinical studies in the united States of America and global locations. URL: http://clinicaltrials.gov/ct2/results?term=rilonacept Accessed October 12, 2009.